Compounded tirzepatide is not FDA-approved and is prepared by state-licensed compounding pharmacies
At the 12 mg dose, nausea was reported by approximately 45% of participants
Guraud F, Atalay M, Bresgen N, Cipak A, Eckl PM, Huc L, et al
Priority review puts it at Q2Q3 2027
By combining appetite regulation with increased energy expenditure, retatrutide supports weight loss through two major mechanisms: Reduced caloric intake from improved satiety Increased metabolic activity that helps burn stored fat This dual action helps explain why retatrutide is often associated with more pronounced weight loss compared to therapies that rely on appetite suppression alone
Many people lean on manufacturer savings cards, clinic membership programs, or compounded versions where appropriate